Brief: Cantargia Publishes Preclinical Results Highlighting Can10's Potential To Inhibit Vascular Inflammation
19/05/2025 06:34
May 19 (Reuters) - Cantargia AB CANTA.ST: PUBLISHES PROMISING PRECLINICAL RESULTS HIGHLIGHTING CAN10'S POTENTIAL TO INHIBIT VASCULAR INFLAMMATION IL1RAP EXPRESSION POSITIVELY CORRELATES WITH INFLAMMATORY MARKERS IN HUMAN ATHEROSCLEROTIC PLAQUES IL1RAP BLOCKING ANTIBODIES INHIBIT ENDOTHELIAL ACTIVATION, NEUTROPHIL ADHESION INDUCED BY IL-1, IL-33 AND IL-36 Source text: ID:nMFN45PpMN Further company coverage: CANTA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML